20 results
Search Results
2. Cytomegalovirus and Epstein–Barr virus co-infected young and middle-aged adults can have an aging-related T-cell phenotype.
- Author
-
Hofstee, Marloes I., Cevirgel, Alper, de Zeeuw-Brouwer, Mary-Lène, de Rond, Lia, van der Klis, Fiona, and Buisman, Anne-Marie
- Subjects
MIDDLE-aged persons ,YOUNG adults ,EPSTEIN-Barr virus ,IMMUNOSENESCENCE ,T cells ,AGE groups ,IMMUNOGLOBULINS - Abstract
Cytomegalovirus (CMV) is known to alter circulating effector memory or re-expressing CD45RA
+ (TemRA) T-cell numbers, but whether Epstein–Barr virus (EBV) does the same or this is amplified during a CMV and EBV co-infection is unclear. Immune cell numbers in blood of children and young, middle-aged, and senior adults (n = 336) were determined with flow cytometry, and additional multivariate linear regression, intra-group correlation, and cluster analyses were performed. Compared to non-infected controls, CMV-seropositive individuals from all age groups had more immune cell variance, and CMV+ EBV− senior adults had more late-differentiated CD4+ and CD8+ TemRA and CD4+ effector memory T-cells. EBV-seropositive children and young adults had a more equal immune cell composition than non-infected controls, and CMV− EBV+ senior adults had more intermediate/late-differentiated CD4+ TemRA and effector memory T-cells than non-infected controls. CMV and EBV co-infected young and middle-aged adults with an elevated BMI and anti-CMV antibody levels had a similar immune cell composition as senior adults, and CMV+ EBV+ middle-aged adults had more late-differentiated CD8+ TemRA, effector memory, and HLA-DR+ CD38− T-cells than CMV+ EBV− controls. This study identified changes in T-cell numbers in CMV- or EBV-seropositive individuals and that some CMV and EBV co-infected young and middle-aged adults had an aging-related T-cell phenotype. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Deep learning model to predict Epstein–Barr virus associated gastric cancer in histology.
- Author
-
Jeong, Yeojin, Cho, Cristina Eunbee, Kim, Ji-Eon, Lee, Jonghyun, Kim, Namkug, Jung, Woon Yong, Sung, Joohon, Kim, Ju Han, Lee, Yoo Jin, Jung, Jiyoon, Pyo, Juyeon, Song, Jisun, Park, Jihwan, Moon, Kyoung Min, and Ahn, Sangjeong
- Subjects
DEEP learning ,STOMACH cancer ,EPSTEIN-Barr virus ,HEMATOXYLIN & eosin staining ,LABOR costs ,HISTOLOGY ,DECISION making - Abstract
The detection of Epstein–Barr virus (EBV) in gastric cancer patients is crucial for clinical decision making, as it is related with specific treatment responses and prognoses. Despite its importance, the limited medical resources preclude universal EBV testing. Herein, we propose a deep learning-based EBV prediction method from H&E-stained whole-slide images (WSI). Our model was developed using 319 H&E stained WSI (26 EBV positive; TCGA dataset) from the Cancer Genome Atlas, and 108 WSI (8 EBV positive; ISH dataset) from an independent institution. Our deep learning model, EBVNet consists of two sequential components: a tumor classifier and an EBV classifier. We visualized the learned representation by the classifiers using UMAP. We externally validated the model using 60 additional WSI (7 being EBV positive; HGH dataset). We compared the model's performance with those of four pathologists. EBVNet achieved an AUPRC of 0.65, whereas the four pathologists yielded a mean AUPRC of 0.41. Moreover, EBVNet achieved an negative predictive value, sensitivity, specificity, precision, and F1-score of 0.98, 0.86, 0.92, 0.60, and 0.71, respectively. Our proposed model is expected to contribute to prescreen patients for confirmatory testing, potentially to save test-related cost and labor. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Uncovering early events in primary Epstein-Barr virus infection using a rabbit model.
- Author
-
Reguraman, Narendran, Hassani, Asma, Philip, Pretty, and Khan, Gulfaraz
- Subjects
EPSTEIN-Barr virus ,EPSTEIN-Barr virus diseases ,GERMINAL centers ,ANIMAL tagging ,INFECTION ,RABBITS - Abstract
Epstein-Barr virus (EBV) is an oncogenic herpesvirus implicated in the pathogenesis of several malignant and non-malignant conditions. However, a number of fundamental aspects about the biology of EBV and the mechanism(s) by which this virus induces pathology remain unknown. One major obstacle has been the lack of a suitable animal model for EBV infection. In this study, using our recently established rabbit model of EBV infection, we examined the early events following primary EBV infection. We show that, both immunocompetent and immunosuppressed animals were readily susceptible to EBV infection. However, immunosuppressed animals showed marked splenomegaly and widespread infection. Following EBV infection, the virus primarily targeted naïve IgM
+ , CD20+ , CD21+ and CD79a+ B cells. Infected cells expressed varying sets of viral latent/lytic gene products. Notably, co-expression of latent and lytic proteins in the same cell was not observed. Infected cells in type 0/1 latency (EBERs+ ), were small and proliferating (Ki67+ ). By contrast, cells in type 2/3 latency (LMP1+ ), were large, non-proliferating (Ki-67− ) and p53+ . Although infected B-cells were widely present in splenic follicles, they did not express germinal center marker, BCL-6. Taken together, this study shows for the first time, some of the early events following primary EBV infection. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients.
- Author
-
Chen, Ting, Song, Jiayi, Liu, Hongli, Zheng, Hongmei, and Chen, Changzheng
- Subjects
EPSTEIN-Barr virus ,COVID-19 pandemic ,SEROLOGY ,MIXED infections ,INFLAMMATION - Abstract
The objective of this study was to detect the Epstein–Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV/SARS-CoV-2 coinfection group and SARS-CoV-2 infection alone group according to the serological results of EBV, and the characteristics differences between the two groups were compared. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, thirty-seven (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV/SARS-CoV-2 coinfection patients had a 3.09-fold risk of having a fever symptom than SARS-CoV-2 infection alone patients (95% CI 1.11–8.56; P = 0.03). C-reactive protein (CRP) (P = 0.02) and the aspartate aminotransferase (AST) (P = 0.04) in EBV/SARS-CoV-2 coinfection patients were higher than that in SARS-CoV-2 infection alone patients. EBV/SARS-CoV-2 coinfection patients had a higher portion of corticosteroid use than the SARS-CoV-2 infection alone patients (P = 0.03). We find a high incidence of EBV coinfection in COVID-19 patients. EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Evolution of antibody titres against Epstein–Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients.
- Author
-
Pérez-Pérez, Silvia, Cuello, Juan Pablo, Martínez-Ginés, Marisa, Pardo-Rodríguez, Beatriz, García-Domínguez, José Manuel, Domínguez-Mozo, María Inmaculada, Lozano-Ros, Alberto, García-Martínez, María Ángel, Higueras, Yolanda, Meldaña-Rivera, Ariana, Goicochea-Briceño, Haydee, Tejeda-Velarde, Amalia, Fernández-Velasco, Jose Ignacio, Medina, Silvia, Arroyo, Rafael, Villar, Luisa María, and Álvarez-Lafuente, Roberto
- Subjects
EPSTEIN-Barr virus ,MULTIPLE sclerosis ,RETROVIRUSES ,MESSENGER RNA ,GENE expression - Abstract
Epstein–Barr virus (EBV), human herpesvirus 6A/B (HHV-6A/B) and multiple sclerosis (MS)-associated retrovirus (MSRV) have been described as possible MS triggers. We analysed antibody titres against EBV and HHV-6, and MSRV envelope (env) mRNA expression, in the serum of pregnant multiple sclerosis patients (P-MS) to study their possible link to the clinical activity of MS during pregnancy and postpartum and their possible role as relapse predictors. For that purpose, serum samples were collected from 71 pregnant women (50 pregnant MS and 21 pregnant healthy controls—P-HC) during pregnancy and postpartum. Relating to antibody titres, IgM antibody titres against HHV-6A/B were significantly higher in P-MS than in P-HC both in each pregnancy trimester and in the postpartum period. Moreover, IgM antibody titres against HHV-6A/B were higher in P-MS who suffered a relapse during the postpartum. Regarding MSRV env mRNA expression, the prevalence in the first trimester of pregnancy was significantly higher in P-MS who suffered relapses during pregnancy. Summing it up, high IgM antibody titres against HHV-6A/B and MSRV env mRNA expression during the first trimester of pregnancy could act as relapse predictors for the gestation/postpartum periods. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. The influence of human genetic variation on Epstein–Barr virus sequence diversity.
- Author
-
Rüeger, Sina, Hammer, Christian, Loetscher, Alexis, McLaren, Paul J., Lawless, Dylan, Naret, Olivier, Depledge, Daniel P., Morfopoulou, Sofia, Breuer, Judith, Zdobnov, Evgeny, Fellay, Jacques, the Swiss HIV Cohort Study, Aebi-Popp, Karoline, Anagnostopoulos, Alexia, Battegay, Manuel, Bernasconi, Enos, Böni, Jürg, Braun, Dominique, Bucher, Heiner, and Calmy, Alexandra
- Subjects
HUMAN genetic variation ,EPSTEIN-Barr virus ,VIRAL genomes ,T cells ,VIREMIA - Abstract
Epstein–Barr virus (EBV) is one of the most common viruses latently infecting humans. Little is known about the impact of human genetic variation on the large inter-individual differences observed in response to EBV infection. To search for a potential imprint of host genomic variation on the EBV sequence, we jointly analyzed paired viral and human genomic data from 268 HIV-coinfected individuals with CD4 + T cell count < 200/mm
3 and elevated EBV viremia. We hypothesized that the reactivated virus circulating in these patients could carry sequence variants acquired during primary EBV infection, thereby providing a snapshot of early adaptation to the pressure exerted on EBV by the individual immune response. We searched for associations between host and pathogen genetic variants, taking into account human and EBV population structure. Our analyses revealed significant associations between human and EBV sequence variation. Three polymorphic regions in the human genome were found to be associated with EBV variation: one at the amino acid level (BRLF1:p.Lys316Glu); and two at the gene level (burden testing of rare variants in BALF5 and BBRF1). Our findings confirm that jointly analyzing host and pathogen genomes can identify sites of genomic interactions, which could help dissect pathogenic mechanisms and suggest new therapeutic avenues. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
- Author
-
Nakano, Hiroshi, Saito, Motonobu, Nakajima, Shotaro, Saito, Katsuharu, Nakayama, Yuko, Kase, Koji, Yamada, Leo, Kanke, Yasuyuki, Hanayama, Hiroyuki, Onozawa, Hisashi, Okayama, Hirokazu, Fujita, Shotaro, Sakamoto, Wataru, Saze, Zenichiro, Momma, Tomoyuki, Mimura, Kosaku, Ohki, Shinji, Goto, Akiteru, and Kono, Koji
- Subjects
STOMACH cancer ,PROTEIN expression ,EPIGENETICS ,EPSTEIN-Barr virus ,TUMOR microenvironment - Abstract
Epstein-Barr virus-positive gastric cancer [EBV (+) GC] is a distinct GC subtype with unique genetic and epigenetic aberrations. Here, we examined resected GC samples and publicly available microarray data and The Cancer Genome Atlas (TCGA) database to identify the mechanism underlying overexpression of PD-L1 in EBV (+) GC. We found that high levels of PD-L1 overexpression in EBV (+) GC were caused by focal amplification of CD274. By contrast, relatively high expression of PD-L1 in tumor tissue and infiltrating immune cells correlated with CD8 lymphocyte infiltration and IFN-γ expression via IRF3 activation. Since we reported previously that PD-L1 expression is associated both with the presence of CD8 T cells in the tumor microenvironment and with IFN-γ expression in GC, we examined a database to see whether IFN-γ-associated overexpression of PD-L1 plays a significant role in EBV (+) GC. Immunohistochemical staining showed that expression of the IRF3 signature in clinical GC samples was higher in EBV (+) than in EBV (−) cases. The data presented herein reveal a unique dual mechanism underlying PD-L1 overexpression in EBV (+) GC: high focal amplification of CD274 or IFN-γ-mediated signaling via activation of IRF3. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinoma.
- Author
-
Tao, Dan, Zhang, Ningning, Huang, Qingqing, Ge, Chuang, Li, Qicheng, Li, Shujie, Weng, Kegui, Guo, Qishuai, Sui, Jiangdong, Wang, Can, Zhang, Xin, and Wang, Ying
- Subjects
EPSTEIN-Barr virus ,NASOPHARYNX cancer ,KILLER cells ,LIVER metastasis ,REGRESSION analysis - Abstract
The purpose of this study was to investigate the association of Epstein-Barr virus (EBV) with peripheral blood immune cell counts and clinical outcomes in advanced nasopharyngeal carcinoma (NPC) patients. In a retrospective design, 146 patients with NPC at stage IV were enrolled in this study. The association of EBV status with peripheral blood immune cell counts, distant metastases, and long-term survival in patients with advanced NPC were determined. Eighty-seven (59.6%) of all patients were positive for EBV. Compared with patients with normal NK cell count, patients with lower NK cell count showed a significantly lower EBV viral load (median: 614.0 vs. 2190.0 copies/mL, P = 0.024). EBV-positive patients showed a significantly higher incidence of liver metastasis than EBV-negative patients (32.6% vs. 23.7%, P = 0.021). Multi-variant regression analysis showed that EBV infection was independently associated with liver metastasis (OR: 2.33, P = 0.043). EBV positive patients showed a significantly worse PFS (P = 0.001) and OS (P = 0.001) than EBV negative patients. Multivariate Cox regression analysis revealed that EBV infection was independently associated with a worse PFS (HR: 1.94, P = 0.003), and OS (HR: 2.12, P = 0.014) in advanced NPC. In conclusion, EBV infection is associated with a high risk of liver metastasis and is also an independent negative predictor for PFS and OS in patients with advanced NPC. EBV infection is associated with lower CD8% and higher NK%, while lower NK cell count is associated with lower EBV viral load. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Smoking and Epstein–Barr virus infection in multiple sclerosis development.
- Author
-
Hedström, Anna Karin, Huang, Jesse, Brenner, Nicole, Butt, Julia, Hillert, Jan, Waterboer, Tim, Kockum, Ingrid, Olsson, Tomas, and Alfredsson, Lars
- Subjects
SMOKING ,EPSTEIN-Barr virus ,MULTIPLE sclerosis risk factors ,IMMUNOGLOBULINS - Abstract
It is unclear whether smoking interacts with different aspects of Epstein–Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regarding MS risk. Two Swedish population-based case–control studies were used (6,340 cases and 6,219 matched controls). Subjects with different smoking, EBNA-1 and IM status were compared regarding MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) employing logistic regression. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP). Current and past smokers had higher EBNA-1 antibody levels than never smokers (p < 0.0001). There was an additive interaction between current smoking and high EBNA-1 antibody levels (AP 0.3, 95% CI 0.2–0.4), but not between past smoking and high EBNA-1 antibody levels (AP 0.01, 95% CI − 0.1 to 0.1), with regard to MS risk. An interaction also occurred between current smoking and IM history (AP 0.2, 95% CI 0.004–0.4), but not between past smoking and IM history (AP − 0.06, 95% CI − 0.4 to 0.3). Current smoking increases EBNA-1 antibody levels and acts synergistically with both aspects of EBV infection to increase MS risk, indicating that there is at least one pathway to disease in which both risk factors are involved. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Epstein-Barr virus reactivation in sepsis due to community-acquired pneumonia is associated with increased morbidity and an immunosuppressed host transcriptomic endotype.
- Author
-
Goh, Cyndi, Burnham, Katie L., Ansari, M. Azim, de Cesare, Mariateresa, Golubchik, Tanya, Hutton, Paula, Overend, Lauren E., Davenport, Emma E., Hinds, Charles J., Bowden, Rory, and Knight, Julian C.
- Subjects
EPSTEIN-Barr virus ,IMMUNE system ,INTENSIVE care units ,SEPSIS ,IMMUNOSUPPRESSION - Abstract
Epstein-Barr virus (EBV) reactivation is common in sepsis patients but the extent and nature of this remains unresolved. We sought to determine the incidence and correlates of EBV-positivity in a large sepsis cohort. We also hypothesised that EBV reactivation would be increased in patients in whom relative immunosuppression was the major feature of their sepsis response. To identify such patients we aimed to use knowledge of sepsis response subphenotypes based on transcriptomic studies of circulating leukocytes, specifically patients with a Sepsis Response Signature endotype (SRS1) that we have previously shown to be associated with increased mortality and features of immunosuppression. We assayed EBV from the plasma of intensive care unit (ICU) patients with sepsis due to community-acquired pneumonia. In total 730 patients were evaluated by targeted metagenomics (n = 573 patients), digital droplet PCR (n = 565), or both (n = 408). We had previously analysed gene expression in peripheral blood leukocytes for a subset of individuals (n = 390). We observed a 37% incidence of EBV-positivity. EBV reactivation was associated with longer ICU stay (12.9 vs 9.2 days; p = 0.004) and increased organ failure (day 1 SOFA score 6.9 vs 5.9; p = 0.00011). EBV reactivation was associated with the relatively immunosuppressed SRS1 endotype (p = 0.014) and differential expression of a small number of biologically relevant genes. These findings are consistent with the hypothesis that viral reactivation in sepsis is a consequence of immune compromise and is associated with increasing severity of illness although further mechanistic studies are required to definitively illustrate cause and effect. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Monoamine oxidase A is down-regulated in EBV-associated nasopharyngeal carcinoma.
- Author
-
Lee, Hui Min, Sia, Alice Pei Eal, Li, Lili, Sathasivam, Hans Prakash, Chan, Melissa Sue Ann, Rajadurai, Pathmanathan, Tsang, Chi Man, Tsao, Sai Wah, Murray, Paul G., Tao, Qian, Paterson, Ian C., and Yap, Lee Fah
- Subjects
MONOAMINE oxidase ,NASOPHARYNX cancer ,METASTASIS ,EPSTEIN-Barr virus ,AMINES ,MITOCHONDRIAL enzymes - Abstract
Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer that is consistently associated with Epstein-Barr virus (EBV) infection. In this study, we identify for the first time a role for monoamine oxidase A (MAOA) in NPC. MAOA is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines. Depending on the cancer type, MAOA can either have a tumour-promoting or tumour-suppressive role. We show that MAOA is down-regulated in primary NPC tissues and its down-regulation enhances the migration of NPC cells. In addition, we found that EBV infection can down-regulate MAOA expression in both pre-malignant and malignant nasopharyngeal epithelial (NPE) cells. We further demonstrate that MAOA is down-regulated as a result of IL-6/IL-6R/STAT3 signalling and epigenetic mechanisms, effects that might be attributed to EBV infection in NPE cells. Taken together, our data point to a central role for EBV in mediating the tumour suppressive effects of MAOA and that loss of MAOA could be an important step in the pathogenesis of NPC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines.
- Author
-
Kotaki, Ryutaro, Kawashima, Masaharu, Yamamoto, Yuichiro, Higuchi, Hiroshi, Nagashima, Etsuko, Kurosaki, Natsumi, Takamatsu, Masako, Kikuti, Yara Yukie, Imadome, Ken-Ichi, Nakamura, Naoya, and Kotani, Ai
- Subjects
DASATINIB ,EPSTEIN-Barr virus ,LYMPHOBLASTOID cell lines ,CARCINOGENESIS ,DRUG efficacy - Abstract
Latent infection of Epstein-Barr virus (EBV) is associated with a poor prognosis in patients with B cell malignancy. We examined whether dasatinib, a multi kinase inhibitor, which is broadly used for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia is effective on EBV-positive B cell malignancies, using lymphoblastoid cell lines (LCLs) in vitro and in vivo. As a result, in vitro experiments showed that dasatinib induced cell death of the EBV-LCLs which was not accompanied with a lytic reactivation of EBVs. To evaluate the effectiveness in EBV latency type III represented by immunodeficiency lymphoma, LCL-inoculated immunodeficient NOD/shi-scid/Il2rg
nul (NOG) mice were treated with dasatinib. However, in vivo experiments revealed that dasatinib treatment exacerbated tumor cell infiltration into the spleen of LCL-inoculated NOG mice, whereas tumor size at the inoculated site was not affected by the treatment. These results suggest that dasatinib exacerbates the pathogenesis at least in some situations although the drug is effective in vitro. Hence, we should carefully examine a possibility of dasatinib repositioning for EBV+ B cell malignancies. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis.
- Author
-
Afrasiabi, Ali, Parnell, Grant P., Swaminathan, Sanjay, Stewart, Graeme J., and Booth, David R.
- Subjects
MULTIPLE sclerosis risk factors ,EPSTEIN-Barr virus ,PHENOTYPES ,MICRORNA ,GENE expression ,POLIOVIRUS ,THERAPEUTICS - Abstract
Translating the findings of genome wide association studies (GWAS) to new therapies requires identification of the relevant immunological contexts to interrogate for genetic effects. In one of the largest GWAS, more than 200 risk loci have been identified for Multiple Sclerosis (MS) susceptibility. Infection with Epstein-Barr virus (EBV) appears to be necessary for the development of Multiple Sclerosis (MS). Many MS risk loci are associated with altered gene expression in EBV infected B cells (LCLs). We have interrogated this immunological context to identify interaction between MS risk loci and EBV DNA copy number, intrinsic growth rate and EBV encoded miRNA expression. The EBV DNA copy number was associated with significantly more risk alleles for MS than for other diseases or traits. EBV miRNAs BART4-3p and BART3-5p were highly associated with EBV DNA copy number and MS risk loci. The poliovirus receptor (PVR) risk SNP was associated with EBV DNA copy number, PVR and miRNA expression. Targeting EBV miRNAs BART4-3p and BART3-5p, and the gene PVR, may provide therapeutic benefit in MS. This study also indicates how immunological context and risk loci interactions can be exploited to validate and develop novel therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation.
- Author
-
Bajda, Sharon, Blazquez-Navarro, Arturo, Samans, Björn, Wehler, Patrizia, Kaliszczyk, Sviatlana, Amini, Leila, Schmueck-Henneresse, Michael, Witzke, Oliver, Dittmer, Ulf, Westhoff, Timm H., Viebahn, Richard, Reinke, Petra, Thomusch, Oliver, Hugo, Christian, Olek, Sven, Roch, Toralf, and Babel, Nina
- Subjects
EPSTEIN-Barr virus ,KIDNEY transplantation ,LYMPHOPROLIFERATIVE disorders ,B cells ,HOMEOSTASIS ,KIDNEY transplant patients - Abstract
Epstein-Barr virus (EBV) reactivation can lead to serious complications in kidney transplant patients, including post-transplant lymphoproliferative disorder (PTLD). Here, we have assessed the impact of EBV on B cell homeostasis at cellular and humoral level. In a multicenter study monitoring 540 kidney transplant patients during the first post-transplant year, EBV reactivation was detected in 109 patients. Thirteen soluble factors and B cell counts were analyzed in an EBV
+ sub-cohort (N = 54) before, at peak and after EBV clearance and compared to a control group (N = 50). The B cell activating factor (BAFF) was significantly elevated among EBV+ patients. No additional soluble factors were associated with EBV. Importantly, in vitro experiments confirmed the proliferative effect of BAFF on EBV-infected B cells, simultaneously promoting EBV production. In contrast, elevated levels of BAFF in EBV+ patients did not lead to B cell expansion in vivo. Moreover, diminished positive inter-correlations of soluble factors and alterations of the bi-directional interplay between B cell and soluble factors were observed in EBV+ patients at peak and after clearance. Our data suggest that such alterations may counteract the proliferative effect of BAFF, preventing B cell expansion. The role of these alterations in lymphoma development should be analyzed in future studies. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. High MHC-II expression in Epstein–Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentation.
- Author
-
Ghasemi, Farhad, Tessier, Tanner M., Gameiro, Steven F., Maciver, Allison H., Cecchini, Matthew J., and Mymryk, Joe S.
- Subjects
EPSTEIN-Barr virus ,STOMACH cancer ,CANCER cells ,ANTIGENS ,T cells - Abstract
EBV-associated gastric adenocarcinomas (EBVaGCs) often exhibit better clinical outcomes than EBV negative gastric cancers (GCs), which could be related to their consistent expression of foreign viral antigens. Antigen-presenting cells (APCs) present peptide antigens in the context of the class-II major histocompatibility complex (MHC-II). During inflammatory conditions, epithelial cells express MHC-II and function as accessory APCs. Utilizing RNA-seq data from nearly 400 GC patients, we determined the impact of EBV-status on expression of MHC-II components, genes involved in their regulation, and T-cell co-stimulation. Virtually all MHC-II genes were significantly upregulated in EBVaGCs compared to normal tissues, or other GC subtypes. Genes involved in antigen presentation were also significantly upregulated in EBVaGCs, as were the key MHC-II transcriptional regulators CIITA and RFX5. This was unexpected as the EBV encoded BZLF1 protein can repress CIITA transcription and is expressed in many EBVaGCs. Furthermore, MHC-II upregulation was strongly correlated with elevated intratumoral levels of interferon-gamma. In addition, expression of co-stimulatory molecules involved in T-cell activation and survival was also significantly increased in EBVaGCs. Thus, gastric adenocarcinoma cells may functionally contribute to the highly immunogenic tumor microenvironment observed in EBVaGCs via a previously unappreciated role in interferon-induced antigen presentation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
- Author
-
Dominguez-Mozo, Maria Inmaculada, Perez-Perez, Silvia, Villar, Luisa María, Oliver-Martos, Begoña, Villarrubia, Noelia, Matesanz, Fuencisla, Costa-Frossard, Lucienne, Pinto-Medel, María Jesús, García-Sánchez, María Isabel, Ortega-Madueño, Isabel, Lopez-Lozano, Lorena, Garcia-Martinez, Angel, Izquierdo, Guillermo, Fernández, Óscar, Álvarez-Cermeño, Jose Carlos, Arroyo, Rafael, and Alvarez-Lafuente, Roberto
- Subjects
MULTIPLE sclerosis ,NATALIZUMAB ,HUMAN herpesvirus-6 ,EPSTEIN-Barr virus ,BIOMARKERS - Abstract
There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter retrospective longitudinal study including 186 MS patients treated with natalizumab who were followed for 2 years. We analyzed the following variables at recruitment: sex, current age, age at disease onset, disease duration, EDSS, number of T2 and Gd + lesions, IgG and IgM oligoclonal bands, HLA class II (DR, DRB, DQA, DQB, and DRB1*15:01), IgG and IgM antibody titers against human herpesvirus 6 (HHV-6) and the antibody response to Epstein–Barr virus (EBV) through the measurement of the anti-EBNA-1 and anti-VCA IgG titers, in relation to clinical response (no relapses or disability progression), and to NEDA-3 (no evidence of disease activity in terms of clinical response and no changes in MRI scans either) after 2-years follow-up. Baseline EDSS score, baseline EBNA-1 IgG titers and percentage change of HHV6 IgG titers between baseline and 6 month visits were significantly different in clinical responders and in NEDA-3 status (all of them remained significant in the multivariate analysis). We identified three variables for the early identification of natalizumab optimal responders in a rapid and cost-effective approach. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. A Herpesvirus Specific Motif of Epstein-Barr Virus DNA Polymerase Is Required for the Efficient Lytic Genome Synthesis.
- Author
-
Narita, Yohei, Sugimoto, Atsuko, Kawashima, Daisuke, Watanabe, Takahiro, Kanda, Teru, Kimura, Hiroshi, Tsurumi, Tatsuya, and Murata, Takayuki
- Subjects
EPSTEIN-Barr virus ,DNA polymerases ,GENOMES ,HERPESVIRUS diseases ,VIRUS diseases - Abstract
Epstein-Barr virus (EBV) is associated with several malignancies, including Burkitt lymphoma and nasopharyngeal carcinoma. To overcome such disorders, understanding the molecular mechanisms of the EBV replication is important. The EBV DNA polymerase (Pol) is one of the essential factors for viral lytic DNA replication. Although it is well known that its C-terminal half, possessing DNA polymerase and 3'-5' exonuclease activity, is highly conserved among Family B Pols, the NH
2 -terminal half has yet to be characterized in detail. In this study, we show that a stretch of hydrophobic amino acids within the pre-NH2 -terminal domain of EBV Pol plays important role. In addition, we could identify the most essential residue for replication in the motif. These findings will shed light on molecular mechanisms of viral DNA synthesis and will help to develop new herpesviruses treatments. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
19. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.
- Author
-
Chan, King Chi, Chan, Lai Sheung, Ip, Joseph Chok Yan, Lo, Carman, Lo, Kwok Wai, Yip, Timothy Tak Chun, Ngan, Roger Kai Cheong, Wong, Ricky Ngok Shun, Mak, Nai Ki, Ng, Wai Tong, Lee, Anne Wing Mui, Tsao, George Sai Wah, Kahn, Michael, and Lung, Maria Li
- Subjects
NASOPHARYNX cancer ,CARCINOMA ,CREB-binding protein ,CATENINS ,EPSTEIN-Barr virus ,CISPLATIN ,CANCER stem cells ,CANCER treatment - Abstract
Nasopharyngeal carcinoma (NPC) is an EBV-associated epithelial malignancy prevalent in southern China. Presence of treatment-resistant cancer stem cells (CSC) may associate with tumor relapse and metastasis in NPC. ICG-001 is a specific CBP/β-catenin antagonist that can block CBP/β-catenin-mediated transcription of stem cell associated genes and enhance p300/β-catenin-mediated transcription, thereby reducing the CSC-like population via forced differentiation. In this study, we aimed to evaluate the effect of ICG-001 on the CSC-like population, and the combination effect of ICG-001 with cisplatin in the C666-1 EBV-positive NPC cells. Results showed that ICG-001 inhibited C666-1 cell growth and reduced expression of CSC-associated proteins with altered expression of epithelial-mesenchymal transition (EMT) markers. ICG-001 also inhibited C666-1 tumor sphere formation, accompanied with reduced SOX2
hi /CD44hi CSC-like population. ICG-001 was also found to restore the expression of a tumor suppressive microRNA-145 (miR-145). Ectopic expression of miR-145 effectively repressed SOX2 protein expression and inhibited tumor sphere formation. Combination of ICG-001 with cisplatin synergistically suppressed in vitro growth of C666-1 cells and significantly suppressed growth of NPC xenografts. These results suggested that therapeutically targeting of the CBP/β-catenin signaling pathway with ICG-001 can effectively reduce the CSC-like population and combination with cisplatin can effectively suppress the growth of NPC. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
20. The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice.
- Author
-
Zhang, Lianhai, Liu, Yiqiang, Wang, Xiaohong, Tang, Zhiyu, Li, Shuangxi, Hu, Ying, Zong, Xianglong, Wu, Xiaojiang, Bu, Zhaode, Wu, Aiwen, Li, Ziyu, Li, Zhongwu, Huang, Xiaozheng, Jia, Ling, Kang, Qiang, Liu, Yong, Sutton, David, Wang, Lai, Luo, Lusong, and Ji, Jiafu
- Subjects
ANIMAL models of cancer ,LYMPHOMAS in animals ,LABORATORY mice ,IMMUNODEFICIENCY ,XENOGRAFTS ,INFLAMMATION ,CD45 antigen ,EPSTEIN-Barr virus - Abstract
Xenotransplantation of human cancers into immunodeficient mice is a very useful approach for studying human tumor biology. However, the occasional occurrence of lymphomagenesis in some mice can spoil the model and must be investigated in detail. We found that a high percentage (32.5%, 26/80) of cancer patient-derived xenografts (PDXs) resembled lymphoma in NOD/SCID mice. Of the 26 xenografts, 23 were human-derived expressing human CD45 (hCD45+) and proved to be of the B-cell subtype (CD3-/CD20+), and they were all positive for Epstein - Barr virus (EBV). The remaining 3 xenografts proved to be mouse-derived for both hCD45- and negative amplification of a human gene. The most interesting finding is that gastric cancer had much higher rates (24/126, 19.0%) of lymphoma formation in the PDX model than did colorectal cancer (1/43, 2.3%). Statistical analysis revealed that cancer type and inflammation in the parent tumor are significantly associated with lymphomagenesis. Further validation discovered lymphomagenesis by inoculating only gastritis mucosa. Therefore, our findings suggest that it is necessary to take precautions when directly xenografting cancer tissues with remarkable baseline inflammation, such as gastric cancer into immunodeficient NOD/SCID strains. Further, the established xenograft models should be validated by both leukocyte markers and human gene signatures. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.